Camurus (CAMX.ST) said the FDA accepted its resubmitted NDA for CAM2029 for review in the treatment of acromegaly. The regulatory acceptance is an incremental positive step toward potential approval, though no decision timing or efficacy/safety outcome was provided.
Camurus (CAMX.ST) said the FDA accepted its resubmitted NDA for CAM2029 for review in the treatment of acromegaly. The regulatory acceptance is an incremental positive step toward potential approval, though no decision timing or efficacy/safety outcome was provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
